Cynomolgus ALCAM Protein (His Tag)

ALCAM

100ug (NPP4403) Please inquiry

Catalog Number	P90227-C08H
Organism Species	Cynomolgus
Host	Human Cells
Synonyms	ALCAM
Molecular Weight	The recombinant cynomolgus ALCAM comprises 510 amino acids and has a calculated molecular mass of 57.3 KDa. The apparent molecular mass of the protein is approximately 65-68 KDa respectively in SDS-PAGE.
predicted N	Trp 28
SDS-PAGE
Purity	> 95 % as determined by SDS-PAGE
Protein Construction	A DNA sequence encoding the cynomolgus ALCAM (G7NZQ8) (Met1-Ala526) was expressed with a polyhistidine tag at the C-terminus.
Bio-activity	Immobilized Cynomolgus ALCAM-His at 10 μg/ml (100 μl/well) can bind mouse CD6-Fc (P50711-M02H), The EC₅₀ of mouse CD6-Fc (P50711-M02H) is 0.07-0.15 μg/ml.
Research Area	Developmental Biology \|Embryogenesis \|Germ Layer Formation \|Mesoderm Marker
Formulation	Lyophilized from sterile PBS, pH 7.4. 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background	Activated leukocyte cell adhesion molecule (ALCAM)/Cluster of differentiation (CD166) is a type I transmembrane cell adhesion molecule belonging to the Ig superfamily and a ligand for CD6 that is expressed on T lymphocytes. The extracellular domain of ALCAM contains five Ig-like domains (three Ig-like C2-type domains and two Ig-like V-type domains), of which the amino-terminal V1 domain is essential for ligand binding and ALCAM-mediated cell aggregation. ALCAM mediates both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. ALCAM/CD6 interaction plays a role in T cell development and T cell regulation, as well as in the binding of T- and B-cells to activated leukocytes. Recently, homophilic (ALCAM-ALCAM) adhesion was shown to play important roles in tight cell-to-cell interaction and regulation of stem cell differentiation. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response and tumor progression. And CD166 is regarded as a potential novel breast cancer indicator and therapeutic target.
Reference	Swart GW. (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 81(6): 313-21. Fujiwara H, et al. (2003) Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab. 88(7): 3437-43. Jezierska A, et al. (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 12(8): BR263-73. Kahlert C, et al. (2009) Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 101(3): 457-64.